Products Site 05/08 Takara Bio Group’s Mid-term Management Plan 05/01 Takara Bio submitted an Investigational New Drug application for a Phase II clinical trial of HF10 anti-cancer therapy to the Food and Drug Administration 03/13 Clinical research protocol of gene therapy targeting B cell non-Hodgkin Lymphoma was approved by Japanese Ministry 03/03 Takara Bio obtains a governmental grant for commercialization of its TCR gene therapy projects 02/10 Submission of the application for Investigator-initiated Phase I clinical trials of MAGE-A4 TCR gene therapy as Japan’s first genetic immunotherapy for cancer return to top Message from the president Corporate Data Corporate Executives Directions to Takara Bio Corporate Governance Consolidated Subsidiaries Bioindustry Gene Therapy AgriBio Copyright © TAKARA BIO INC. All rights reserved.